

10/725221

-19-

PC27831A

**REMARKS**

Claims 1-37 remain in the application. Only Claim 1 is in independent form.

Claims 1-37 stand rejected 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement. Specifically, it is stated in the Office Action that the "Specification while being enabling for the method for treating said disorders, include, without limitation, chronic and neuropathic pain, migraine therapy, urge, stress and mixed urinary incontinence...these claims does [sic] does not reasonably provide enablement for prevention."

Applicants have amended Claim 1 to remove "prevention" therefrom.

Applicants respectfully submit that the amendment to Claim 1 overcomes the rejection under 35 U.S.C. § 112, first paragraph, and withdrawal of the rejection is respectfully submitted.

Claims 1-37 stand rejected under 35 U.S.C. § 102(a) and (e) as allegedly being anticipated by Beck et al..

Claims 1-37 stand rejected under 35 U.S.C. § 103(a) over Boltze et al. (US 4,564,613), Beck et al. (US 6,579,885), and Black's Medical Dictionary as allegedly rendering obvious compounds of Formula I-IV for the treatment of various central nervous system disorders such as headache, migraine, and pain.

In order to expedite the prosecution of the present application, Applicants have amended claim 1 to define a method of treating urge, stress, or mixed urinary incontinence comprising administration of an effective amount of a compound of Formula I-IV. Applicants respectfully submit that none of the cited references alone or in combination teach or suggest the use of the compounds of Formula I-IV for treatment of these types of urinary incontinence. Applicants reserve their right to file divisional applications on the non-claimed subject matter. It is consequently respectfully submitted that the claims are clearly patentable over the cited prior art combinations, even if the combinations were to be applied, in opposition to applicable law, and reconsideration of the rejections is respectfully requested.

10/725221

-20-

PC27831A


Claims 1-37 stand provisionally rejected under the judicially created doctrine of double patenting over Claims 1-32 of copending Application No. 09/902,845. Applicants respectfully submit that upon allowance of claims in the present application that Applicants will resolve the outstanding double patenting rejection pending in the present application.

In view of the present amendment and foregoing remarks, reconsideration of the rejection and advance of the case to issue are respectfully requested.

The Commissioner is authorized to charge any fee or credit any overpayment in connection with the communication to our deposit account number 23-0455.

Respectfully submitted,

Dated: 3/10/06



David R. Kurlandsky  
Registration No. 41,505  
Warner-Lambert Company LLC  
2800 Plymouth Road  
Ann Arbor, Michigan 48105  
Telephone: (734) 622-7304  
Facsimile: (734) 622-1553